絞り込み

16287

広告

「"maemondo m"[Author]」の検索結果

83件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.

1471PFINAL RESULT OF RANDOMIZED PHASE 2 TRIAL COMPARING AMRUBICIN (A) WITH RE-CHALLENGE OF PLATINUM DOUBLET (P) IN PATIENTS (PTS) WITH SENSITIVE-RELAPSED SMALL-CELL LUNG CANCER (SCLC): NJLCG0702.

1284PRANDOMIZED PHASE II STUDY OF CONCURRENT VERSUS SEQUENTIAL ALTERNATING GEFITINIB AND CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER (NSCLC) WITH SENSITIVE EGFR MUTATIONS: NEJ005/TCOG0902.

1465PUPDATED DATA ON CLINICAL AND MOLECULAR PROFILE OF SURGICALLY RESECTED SMALL CELL LUNG CANCER: INTERGROUP STUDY WITH FIGHT002 AND HOT1301.

1470PTHE EFFECT OF PROPHYLACTIC CRANIAL IRRADIATION (PCI) IN THE PATIENTS WITH EXTENSIVE-DISEASE SMALL-CELL LUNG CANCER (ED-SCLC): RESULTS OF A JAPANESE RANDOMIZED PHASE III TRIAL.

1476PFINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY COMPARING CARBOPLATIN PLUS IRINOTECAN (CI) VERSUS CARBOPLATIN PLUS AMRUBICIN (CA) FOR EXTENSIVE DISEASE SMALL-CELL LUNG CANCER: NJLCG0901.

A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.

Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

Phase I trial of bi-weekly docetaxel combined with carboplatin for patients with non-small cell lung cancer.

Final result of phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for elderly patients with small cell lung cancer (SCLC).

First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group.

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.

Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Sort by
※並べ替えは表示に時間がかかります